Taken together, these findings suggest that AR suppressed TDO2 and GR transcription in androgen-sensitive prostate cancer cells, whereas ADT relieved AR suppression and resulted in TDO2 transcription and expression of GR, which then took over the role of AR to further activate TDO2 transcription and maintain the recurrent CRPC stage. This evidence concerns the gene AR and prostate carcinoma.